A single intravitreal injection of 4D-150 helped patients with wet age-related macular degeneration maintain visual acuity ...

Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) are currently up over 20.6% after the company released positive results from its Spectra trial. The Spectra trial evaluates 4D-150 in patients with ...

4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level 4D-150 demonstrated durable and dose-dependent clinical activity with sustained gains in ...

(RTTNews) - Shares of 4D Molecular Therapeutics (FDMT) are up over 26% to $5.69 in premarket trading Friday, following positive 60-week data from its Phase II SPECTRA trial. The SPECTRA trial is ...

4D Molecular Therapeutics has posted 60-week data on a gene therapy, providing evidence of durability in diabetic macular edema (DME) and sending its stock up more than 40% in premarket trading. The ...